Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 1/2005

01-01-2005 | Review Paper

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells

Authors: Steven De Vleeschouwer, Stefaan W. Van Gool, Frank Van Calenbergh

Published in: Child's Nervous System | Issue 1/2005

Login to get access

Abstract

Review

In this review, we discuss immunotherapy for malignant gliomas.

Emphasis

The emphasis is on the novel strategy of active specific immunotherapy using dendritic cells as antigen-presenting cells, especially its theoretical concepts and advantages, specific requirements, critical issues, pre-clinical and early clinical experience. Dendritic cell vaccination is situated in the diversity of other immunotherapeutical approaches.

Further discussion

Future directions, challenges, and drawbacks will be discussed.
Literature
1.
Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106–113CrossRef
2.
Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89CrossRefPubMed
3.
Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463–468CrossRefPubMed
4.
Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP (1997) A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. J Neuroimmunol 78:34–46CrossRefPubMed
5.
6.
Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182PubMed
7.
Bertrand I, Mannen H (1960) Etude des réactions vasculaires dans les astrocytomes. Rev Neurol (Paris) 102:3–19
8.
Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab’)2–a preliminary report. J Neurooncol 24:109–122PubMed
9.
Black KL, Chen K, Becker DP, Merrill JE (1992) Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 77:120–126PubMed
10.
Bloom HJ, Peckham MJ, Richardson AE, Alexander PA, Payne PM (1973) Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 27:253–267
11.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000) Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 20:2665–2676PubMed
12.
Boethius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68:239–251
13.
Boiardi A, Silvani A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193–197CrossRefPubMed
14.
Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143–2152PubMed
15.
Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13:507–512CrossRefPubMed
16.
Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMed
17.
DeVleeschouwer S, VanCalenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff J, Plets C, VanGool S (2004) Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg (in press)
18.
Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216–232CrossRefPubMed
19.
Elliott L, Brooks W, Roszman T (1987) Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919–922PubMed
20.
Engleman EG, Fong L (2003) Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 106:10–15CrossRefPubMed
21.
Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909–2914CrossRefPubMed
22.
Farkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H, Mantyla M (1994) Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138–141PubMed
23.
Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487–494CrossRefPubMed
24.
Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482–9487CrossRefPubMed
25.
Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E (1982) Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413–2419PubMed
26.
Gallimore A, Sakaguchi S (2002) Regulation of tumour immunity by CD25+ T cells. Immunology 107:5–9CrossRefPubMed
27.
Gehrmann J, Matsumoto Y, Kreutzberg GW (1995) Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20:269–287CrossRefPubMed
28.
Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513–8519PubMed
29.
Gilboa E, Nair SK, Lyerly HK (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46:82–87CrossRefPubMed
30.
Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP (1995) Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36:548–555PubMed
31.
Glick RP, Lichtor T, Mogharbel A, Taylor CA, Cohen EP (1997) Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41:898–906; discussion 906–907CrossRefPubMed
32.
Gluckman JC, Canque B, Chapuis F, Rosenzwajg M (1997) In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther 3:187–196PubMed
33.
Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893–4897PubMed
34.
Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H (1997) Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7:863–869PubMed
35.
Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33PubMed
36.
Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16–25CrossRefPubMed
37.
Hickey WF, Hsu BL, Kimura H (1991) T-lymphocyte entry into the central nervous system. J Neurosci Res 28:254–260PubMed
38.
Holladay FP, Lopez G, De M, Morantz RA, Wood GW (1992) Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery 30:499–504; discussion 504–505PubMed
39.
Holladay FP, Choudhuri R, Heitz T, Wood GW (1994) Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80:90–96PubMed
40.
Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777–782CrossRefPubMed
41.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58CrossRefPubMed
42.
Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC (1997) Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17:3217–3224PubMed
43.
Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, Oizumi K, Itoh K (1999) Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83:760–764CrossRefPubMed
44.
Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613–621PubMed
45.
Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528–530
46.
Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY (2003) Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64:71–76CrossRefPubMed
47.
Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344CrossRefPubMed
48.
Kikuchi T, Akasaki Y, Abe T, Ohno T (2002) Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 51:424–430CrossRefPubMed
49.
Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15:211–221PubMed
50.
Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45:77–87CrossRefPubMed
51.
Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71:211–217PubMed
52.
Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD (1995) Tumor antigens in astrocytic gliomas. Glia 15:244–256PubMed
53.
Lampson L (1997) Immunobiology of brain tumors: antigens, effectors, and delivery to sites of microscopic tumor in the brain. In: Black P, Loeffler J (eds) Cancer of the nervous system. Blackwell, Cambridge, pp 874–906
54.
Lampson LA, Hickey WF (1986) Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from “histologically normal” to that showing different levels of glial tumor involvement. J Immunol 136:4054–4062PubMed
55.
Lesniak M, Sampath P, Dimeco F, Viglione M, Tyler B, Pardoll D, Brem H (2000) Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurg Focus 9(6) article 6
56.
Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124PubMed
57.
Liau L, Black K, Martin N, Sykes S, Bronstein J, Jouben-Steele L, Mischel P, Belldegrun A, Cloughesy T (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report. Neurosurg Focus 9(6) article 8
58.
Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28:16–23PubMed
59.
Liu Y, Ng K, Lillehei K (2000) Time course analysis and modulating effects of established brain tumor on active specific immunotherapy. Neurosurg Focus 9(6) article 3
60.
Lowe J, MacLennan KA, Powe DG, Pound JD, Palmer JB (1989) Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells. J Pathol 159:143–149PubMed
61.
Mahaley MS Jr, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM (1983) Immunobiology of primary intracranial tumors. VII. Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 59:201–207PubMed
62.
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297–1302CrossRefPubMed
63.
McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD (2000) Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48:1103–1110PubMed
64.
McVicar DW, Davis DF, Merchant RE (1992) In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 76:251–260PubMed
65.
Medawar P (1948) Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58–69
66.
Mellman I, Steinman R (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258CrossRefPubMed
67.
Merchant RE, Grant AJ, Merchant LH, Young HF (1988) Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62:665–671PubMed
68.
Merchant RE, Ellison MD, Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol 8:173–188CrossRefPubMed
69.
Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL (1997) T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415–4425PubMed
70.
Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G (2003) A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol 58:578–586CrossRefPubMed
71.
Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371–380CrossRefPubMed
72.
Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73–78CrossRefPubMed
73.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMed
73.
Nestle FO, Banchereau J, Hart D (2001) Dendritic cells: on the move from bench to bedside. Nat Med 7:761–765CrossRefPubMed
75.
Ni HT, Spellman SR, Jean WC, Hall WA, Low WC (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9CrossRefPubMed
76.
Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA (2000) Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 165:3797–3803PubMed
77.
Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME (1998) Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196–201CrossRefPubMed
78.
Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851–2855PubMed
79.
Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics, 1997. CA Cancer J Clin 47:5–27PubMed
80.
Parney IF, Petruk KC, Zhang C, Farr-Jones M, Sykes DB, Chang LJ (1997) Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 8:1073–1085PubMed
81.
Parney IF, Hao C, Petruk KC (2000) Glioma immunology and immunotherapy. Neurosurgery 46:778–791; discussion 791–792CrossRefPubMed
82.
Pawelec G (1999) Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343–345CrossRefPubMed
83.
Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645–4649PubMed
84.
Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE (2002) Assumptions of the tumor ‘escape’ hypothesis. Semin Cancer Biol 12:81–86CrossRefPubMed
85.
Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80:2733–2742PubMed
86.
Rock KL, Clark K (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721–3726PubMed
87.
Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918–921
88.
Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137–151CrossRefPubMed
89.
Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12:370–374PubMed
90.
Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109–1118CrossRefPubMed
91.
Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD (1997) Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365–1372; discussion 1372–1373CrossRefPubMed
92.
Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH (1992) Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76:513–519PubMed
93.
Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147CrossRefPubMed
94.
Sehgal A, Berger M (2000) Basic concepts of immunology and neuroimmunology. Neurosurg Focus 9(6) article 1
95.
Shortman K, Caux C (1997) Dendritic cell development: multiple pathways to nature’s adjuvants. Stem Cells 15:409–419PubMed
96.
Siesjo P, Visse E, Sjogren HO (1996) Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 19:334–345PubMed
97.
Slingluff CL (1997) Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms. Cancer Immunol Immunother 48:371–373CrossRef
98.
Sloan A, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of Anti-Cd3-activated lymphocytes. Neurosurg Focus 9(6) article 9
99.
Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186:1247–1256CrossRefPubMed
100.
Steinman RM, Adams JC, Cohn ZA (1975) Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 141:804–820PubMed
101.
Suter T, Biollaz G, Gatto D, Bernasconi L, Herren T, Reith W, Fontana A (2003) The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol 33:2998–3006CrossRefPubMed
102.
Tamber M, Rutka J (2003) Pediatric supratentorial high-grade gliomas. Neurosurg Focus 14(2) article 1
103.
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678CrossRefPubMed
104.
Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1–15CrossRefPubMed
105.
Tjoa BA, Salgaller ML (2000) Progress in active-specific immunotherapy of brain malignancies. Expert Opin Investig Drugs 9:2093–2101PubMed
106.
Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368–370
107.
Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94–97
108.
Tseng SH, Hwang LH, Lin SM (1997) Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 20:334–342PubMed
109.
Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K (2002) Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 264:135–151CrossRefPubMed
110.
VanGool S, Vandenberghe P, Boer Md, Ceuppens J (1996) DCD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153:47–83PubMed
111.
VanGool S, VandenHove L, Ceuppens J (2000) Activation of the immune system in cancer patients. Med Pediatr Oncol 37:1–9CrossRef
112.
Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD (1992) Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36:41–55CrossRefPubMed
113.
Vernon ML, Fountain L, Krebs HM, Horta-Barbosa L, Fuccillo DA, Sever JL (1973) Birbeck granules (Langerhans’ cell granules) in human lymph nodes. Am J Clin Pathol 60:771–779PubMed
114.
Von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328–338PubMed
115.
Walker PR, Saas P, Dietrich PY (1997) Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158:4521–4524PubMed
116.
Wekerle H, Linington C, Lassmann H (1986) Cellular immune reactivity within the CNS. Trends Neurol Surg 18:271–276
117.
Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94:954–964PubMed
118.
Weller RO, Engelhardt B, Phillips MJ (1996) Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol 6:275–288PubMed
119.
Wersall P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S, Mellstedt H, Boethius J (1997) Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44:157–164CrossRefPubMed
120.
Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, Lee PK (2003) Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171:4927–4933PubMed
121.
Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF (2002) 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50:1327–1334; discussion 1334–1335CrossRefPubMed
122.
Wood GW, Morantz RA (1983) Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol 1:87–94PubMed
123.
Yamada S, DePasquale M, Patlak CS, Cserr HF (1991) Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 261:H1197–H1204PubMed
124.
Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S (2003) Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99:738–745PubMed
125.
Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172–1179CrossRefPubMed
126.
Yoshida J, Wakabayashi T, Mizuno M, Sugita K, Yoshida T, Hori S, Mori T, Sato T, Karashima A, Kurisu K (1992) Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J Neurosurg 77:78–83PubMed
127.
Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847PubMed
128.
Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E (1991) Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9:1945–1949PubMed
129.
Zeltzer PM, Moilanen B, Yu JS, Black KL (1999) Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. Childs Nerv Syst 15:514–528CrossRefPubMed
130.
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97CrossRefPubMed
Metadata
Title
Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells
Authors
Steven De Vleeschouwer
Stefaan W. Van Gool
Frank Van Calenbergh
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Child's Nervous System / Issue 1/2005
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-004-0994-3

Other articles of this Issue 1/2005

Child's Nervous System 1/2005 Go to the issue

Case Report

Horner’s syndrome resulting from agenesis of the internal carotid artery: report of a third case

Letter to the Editor

Cervical meningocele in association with spinal abnormalities

Original Paper

The incidence of inguinal complications after ventriculoperitoneal shunt for hydrocephalus

Original Paper

CSF shunts in children: endoscopically-assisted placement of the distal catheter

Editorial

The upcoming online manuscript processing for Child’s Nervous System

Invited Paper

Spinal tuberculosis: with reference to the children of northern India